Which drugs may be hit with ne­go­ti­a­tions if the rec­on­cil­i­a­tion bill pass­es? Wall St. an­a­lysts ex­plain

Be­yond the back and forth of whether De­moc­rats’ drug price ne­go­ti­a­tion plan is nec­es­sary to bring down costs, or just a thin­ly veiled at­tempt at price con­trols, the nuts and bolts of the deal mean phar­ma com­pa­nies will in­evitably see the tail ends of cer­tain small mol­e­cule and bi­o­log­ic sales pe­ter out be­fore they oth­er­wise would have in to­day’s mar­ket­place.

While the bill’s text is not set in stone, and the Sen­ate par­lia­men­tar­i­an may still take is­sue with the ex­cise tax that CMS will use to en­sure com­pa­nies com­ply with the ne­go­ti­at­ed prices, SVB Se­cu­ri­ties ex­plained to in­vestors how more than a dozen drugs from Eli Lil­ly, As­traZeneca, Ab­b­Vie and J&J, among oth­ers, would lose out on some rev­enue just be­fore their gener­ic com­peti­tors hit the mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER